PIMA541954
Caplacizumab Recombinant Human Monoclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA541954-Each-of-1 | In Stock | ₹ 45,790.50 |
PIMA541954 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 45,790.50
GST (18%): ₹ 8,242.29
Total Price: ₹ 54,032.79
Antigen
Caplacizumab
Classification
Recombinant Monoclonal
Conjugate
Unconjugated
Gene Alias
ALX-0081; caplacizumab-yhdp; PMP12A2h1-linker AAA-PMP12A2h1; VWF A1 domain
Immunogen
Human VWF A1 domain
Quantity
100 μg
Primary or Secondary
Primary
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Applications
ELISA, SDS-Page
Concentration
1.6 mg/mL
Formulation
20mM citric acid with 0.01% Tween 80, 6.2% sucrose and no preservative
Host Species
Human
Purification Method
Metal-chelate chromatography
Regulatory Status
RUO
Target Species
Chemical
Product Type
Antibody
Target Molecule
Chemical
Related Products
Description
- Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
- Store at 2 to 8 °C for one week
- Store at -20 to -80 °C for twelve months from the date of receipt
- Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker
- Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, 6and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Compare Similar Items
Show Difference
Antigen: Caplacizumab
Classification: Recombinant Monoclonal
Conjugate: Unconjugated
Gene Alias: ALX-0081; caplacizumab-yhdp; PMP12A2h1-linker AAA-PMP12A2h1; VWF A1 domain
Immunogen: Human VWF A1 domain
Quantity: 100 μg
Primary or Secondary: Primary
Content And Storage: -20° C, Avoid Freeze/Thaw Cycles
Form: Liquid
Applications: ELISA, SDS-Page
Concentration: 1.6 mg/mL
Formulation: 20mM citric acid with 0.01% Tween 80, 6.2% sucrose and no preservative
Host Species: Human
Purification Method: Metal-chelate chromatography
Regulatory Status: RUO
Target Species: Chemical
Product Type: Antibody
Target Molecule: Chemical
Antigen:
Caplacizumab
Classification:
Recombinant Monoclonal
Conjugate:
Unconjugated
Gene Alias:
ALX-0081; caplacizumab-yhdp; PMP12A2h1-linker AAA-PMP12A2h1; VWF A1 domain
Immunogen:
Human VWF A1 domain
Quantity:
100 μg
Primary or Secondary:
Primary
Content And Storage:
-20° C, Avoid Freeze/Thaw Cycles
Form:
Liquid
Applications:
ELISA, SDS-Page
Concentration:
1.6 mg/mL
Formulation:
20mM citric acid with 0.01% Tween 80, 6.2% sucrose and no preservative
Host Species:
Human
Purification Method:
Metal-chelate chromatography
Regulatory Status:
RUO
Target Species:
Chemical
Product Type:
Antibody
Target Molecule:
Chemical
Antigen: Flanvotumab
Classification: Recombinant Monoclonal
Conjugate: Unconjugated
Gene Alias: 20D7S; IMC-20D7S
Immunogen: Human TYRP1
Quantity: 100 μg
Primary or Secondary: Primary
Content And Storage: -20° C, Avoid Freeze/Thaw Cycles
Form: Liquid
Applications: ELISA, SDS-Page
Concentration: 1.82 mg/mL
Formulation: PBS with no preservative; pH 7.4
Host Species: Human
Purification Method: Protein A
Regulatory Status: RUO
Target Species: Chemical
Product Type: Antibody
Target Molecule: Chemical
Antigen:
Flanvotumab
Classification:
Recombinant Monoclonal
Conjugate:
Unconjugated
Gene Alias:
20D7S; IMC-20D7S
Immunogen:
Human TYRP1
Quantity:
100 μg
Primary or Secondary:
Primary
Content And Storage:
-20° C, Avoid Freeze/Thaw Cycles
Form:
Liquid
Applications:
ELISA, SDS-Page
Concentration:
1.82 mg/mL
Formulation:
PBS with no preservative; pH 7.4
Host Species:
Human
Purification Method:
Protein A
Regulatory Status:
RUO
Target Species:
Chemical
Product Type:
Antibody
Target Molecule:
Chemical
Antigen: Solitomab
Classification: Recombinant Monoclonal
Conjugate: Unconjugated
Gene Alias: MT110
Immunogen: Human CD3E/EpCAM
Quantity: 100 μg
Primary or Secondary: Primary
Content And Storage: -20° C, Avoid Freeze/Thaw Cycles
Form: Liquid
Applications: ELISA
Concentration: 1.5 mg/mL
Formulation: PBS with no preservative; pH 7.4
Host Species: Mouse
Purification Method: Affinity chromatography
Regulatory Status: RUO
Target Species: Chemical
Product Type: Antibody
Target Molecule: Chemical
Antigen:
Solitomab
Classification:
Recombinant Monoclonal
Conjugate:
Unconjugated
Gene Alias:
MT110
Immunogen:
Human CD3E/EpCAM
Quantity:
100 μg
Primary or Secondary:
Primary
Content And Storage:
-20° C, Avoid Freeze/Thaw Cycles
Form:
Liquid
Applications:
ELISA
Concentration:
1.5 mg/mL
Formulation:
PBS with no preservative; pH 7.4
Host Species:
Mouse
Purification Method:
Affinity chromatography
Regulatory Status:
RUO
Target Species:
Chemical
Product Type:
Antibody
Target Molecule:
Chemical
Antigen: Quilizumab
Classification: Recombinant Monoclonal
Conjugate: Unconjugated
Gene Alias: 47H4; M1 prime; MEMP1972A; RG-7449
Immunogen: Human IGHE
Quantity: 100 μg
Primary or Secondary: Primary
Content And Storage: -20° C, Avoid Freeze/Thaw Cycles
Form: Liquid
Applications: ELISA, SDS-Page
Concentration: 4.05 mg/mL
Formulation: PBS with no preservative; pH 7.5
Host Species: Human
Purification Method: Protein A
Regulatory Status: RUO
Target Species: Chemical
Product Type: Antibody
Target Molecule: Chemical
Antigen:
Quilizumab
Classification:
Recombinant Monoclonal
Conjugate:
Unconjugated
Gene Alias:
47H4; M1 prime; MEMP1972A; RG-7449
Immunogen:
Human IGHE
Quantity:
100 μg
Primary or Secondary:
Primary
Content And Storage:
-20° C, Avoid Freeze/Thaw Cycles
Form:
Liquid
Applications:
ELISA, SDS-Page
Concentration:
4.05 mg/mL
Formulation:
PBS with no preservative; pH 7.5
Host Species:
Human
Purification Method:
Protein A
Regulatory Status:
RUO
Target Species:
Chemical
Product Type:
Antibody
Target Molecule:
Chemical